Green Thumb Indus Sub Vtg

Good day and thank you for standing by. Welcome to Green Thumb Industries Q226 earnings call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would like to now hand the conference over to your first speaker today, Andy Grossman, EVP Capital Markets. Please go ahead.

Thank you, Angelina. Good afternoon and welcome to Green Thumbs' second quarter 2026 earnings call. I'm here today with founder and CEO Ben Kovler, President Anthony Georgiadis, and Chief Financial Officer Matt Faulkner. Today's discussions and responses to questions may include forward-looking statements. These risks and uncertainties are detailed in the earnings press release issued today, along with reports filed with the United States Securities and Exchange Commission and Canadian securities regulators, including our most recent annual report filed on Form 10-K. This report, along with today's earnings release, can be found under the Investors section of our website. Green Thumb assumes no obligation to update or revise any forward-looking statements to reflect events or circumstances that may arise after the date of this call. Throughout the discussion, Green Thumb will refer to non-GAAP financial measures, including EBITDA, normalized EBITDA, and adjusted EBITDA. A reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures is included in our earnings press release and SEC and CEDAR Plus filings. Please note that all financial information is provided in U.S. dollars unless otherwise indicated. Thanks everyone and now here's Ben.

Thanks Andy. Good afternoon everyone and thank you for joining Green Thumb's second quarter 2026 earnings call. Before we get into the numbers, I want to take a step back. We're nearly 12 years into the Green Thumb story, building the company from scratch with no roadmap, no playbook, no guarantee of anything, yet quarter after quarter, year after year, We show up and build brands Americans love. We take care of our team, manage the balance sheet, and do the work. That's the Green Thumb story. Simple, but not easy. We built the company to stand on its own without waiting for federal reform. That discipline is paying off. Medical cannabis is now on Schedule 3 of the Controlled Substances Act. The first domino has fallen. The DEA's broader rescheduling hearing wrapped in mid-July and we expect a decision on the rest of cannabis later this year. This is, in fact, real progress. The direction is clear, even if the timing isn't. When the next domino falls, Green Thumb will be ready with the brands, the balance sheet, and the team to meet the moment. That work is already underway, as we shared on our last call. We've registered some of our state-licensed medical cannabis operations with the DEA, and site inspections have begun. This is important because this makes these operations federally legal. We're also preparing to uplist Green Thumb on a U.S. exchange as the path opens. We anticipate listing the business in full, not in part, and we have open dialogues with both major exchanges. But we didn't get to where we were going by waiting, and we won't start waiting now. The state-level environment is more dynamic than it's been, including changes in Virginia and Texas. But here's the bottom line. DreamThumb is in a strong position. Our business generates cash, and we carry a strong balance sheet, which means we engage the capital markets on our terms. And as the environment changes, we won't be reacting to it. We'll be moving on it from a position of strength. And that strength starts with the results. So let's turn to the quarters. Second quarter revenue came in at $307 million, up 5% year-over-year. Normalized EBITDA was $84 million, or approximately 28% of revenue. Cash flow from operations was $29 million. There's real momentum here, and we're proud of the stability we've built despite ongoing price compression and competition. Our results demonstrate this as we see early signs of potential price stabilization in some markets. We ended the quarter with $284 million in cash on the balance sheet, and that's over a dollar a share. But beyond the numbers, the bigger story this year has been state-level regulatory progress. Positive developments in Virginia and Texas get us excited about future growth. Together, these two states represent broader access for roughly 12% of the country's population. And in both, we already have a head start. Anthony will walk through some of those highlights, but the takeaway is simple. Careful planning and a deep understanding of each market's dynamics means we are ready. That same discipline shapes our current approach to growth through tuck-in deals and steadily expanding retail footprint. We're keeping a close eye on hemp policy with the federal ban set to take effect on November 12th of this year, but you never know. Interestingly, Ohio offers a preview of what could happen across the country. Following the state's own ban on intoxicating hemp, Ohio's regulated market has grown more than 10% based on state-level data. Consumers are moving into the regulated market and we expect hemp demand to keep shifting into cannabis as the ban takes hold. In other words, if the ban takes place, it favors operators with scale, brands, and shelf space already in place. This backdrop matters for one of the fastest growing categories, THC beverages. In our view, beverages are a distinct category from intoxicating hemp products, and we think regulators and industry participants are starting to see the same thing. We remain big believers in the category, and we are optimistic that this transition will eventually carve out a lasting place for THC beverages in the mainstream market. They're already showing up at major events and venues across the country, including Lollapalooza and the United Center, and at retailers like Circle K, Target, and Total Wine. We're paying close attention to the consumer trends, particularly through our investment in Rhythm Inc. And on that note, there's a potential change coming to how Rhythm Inc. appears in Green Thumb's financials, in our results. On August 10th, Rhythm shareholders will vote on a proposal that, if approved, would result in Green Thumb consolidating Rhythm into our financial statements as early as October 10th, 2026. Presenting the combined economics in one place rather than under the equity method that we use today. Nothing will change economically, but our reported results will look different once they include Rhythm. You can find more information on this potential change for Rhythm Inc. in the proxy file by Rhythm with the SEC on July 9th, 2026 on sec.gov and available on the Rhythm website. We believe Green Thumb has created significant value that the market is not currently reflecting. Structural issues in this industry are real, but we never let the things we can't control define the things we can. We are building this company for the next decade or decades, not the next quarter or year. That conviction is why we allocate capital towards repurchasing shares at these levels. During the quarter, we bought back the equivalent of about 8 million shares at an average price of just over $6. And since Q4 2023, we've repurchased approximately 29.5 million shares at an average price of $7 per share, which represents more than $200 million returned to shareholders in a tax-efficient manner. That's roughly 13% of the shares outstanding, so each remaining share represents a 13% bigger portion of the business. So, we'll continue to do exactly what we said we would do, grow the business, take care of our team, return capital to shareholders when it makes sense, and pounce when the opportunity presents itself. all while the environment catches up to the value we've created and continue to build. We are deeply committed to creating long-term value for all of our stakeholders and that will always be the Green Thumb story. With that, I'll turn the call over to Anthony.

Thanks, Ben. The second quarter was a productive one. The company generated $307 million of revenue and $84 million in normalized EBITDA representing 5% year-over-year top-line growth. Unpacking the results, Retail revenue grew just under 4% versus the prior year period, with strong contributions from Minnesota, Connecticut, and Florida. Same store sales on a base of 103 stores were down approximately 1%, a modest step down from the 0.5% decline we reported in Q1. Pricing compression remained a headwind, particularly in Massachusetts, New Jersey, and Pennsylvania, and our teams continued to navigate it effectively through operational discipline, Creative Product Merchandising and Pricing, Brand Strength, and our Omnichannel platform. On the CPG side, gross revenue also grew just under 4% year-over-year, led by Minnesota, Ohio, New Jersey, and New York. We continue to lean into our wholesale business and we're pleased with our market share performance across Illinois, Pennsylvania, Ohio, Maryland, and Minnesota, where we retain the number one position in each state. Turning to capital allocation, we deployed $20 million into the business during the quarter, approximately $5 million in retail CapEx supporting store relocations and buildouts in Pennsylvania, Virginia, and Florida, and $15 million on the wholesale side for capacity expansions and maintenance needs. With Virginia's adult use launch in mid-2027, we're actively evaluating the right level of incremental investment into that market. Full year 2026 CapEx guidance remains approximately $80 million. A quick note on recognition. During the quarter, GTI was named a Time Magazine's list of America's best companies. Selected from more than 7,200 eligible companies across every industry and scored on employee satisfaction, financial performance, and sustainability practices, we were the highest-ranked cannabis company on the list, a genuine honor for our team. On the regulatory front, Virginia and Texas represent two extremely compelling near-term growth catalysts. In Virginia, adult use legislation has been signed and takes effect July 1, 2027. As a reminder, we're one of five licensed medical operators in the state and currently operate six RISE dispensaries and two cultivation facilities. We've been investing and planning ahead of this transition, drawing on the playbook we recently executed in Minnesota, Maryland, and Ohio. The opportunity is immense. Approximately 9 million residents in meaningful geographic proximity to North Carolina, Kentucky, and Tennessee states where cannabis access remains extremely limited. In Texas, we were awarded a conditional license under the Compassionate Use Program on April 1. During Q2, we focused on completing background checks, state paperwork, defining our real estate strategy, and thinking through how to enter the program in a differentiated and scalable way. Texas has a GDP of approximately $3 trillion, the eighth largest global economy. And if the state follows through on expanding its Compassionate Use Program, The long-term upside is significant. We're excited to bring our brands and our enter open scale model to the Lone Star State. Subsequent to quarter end, we had a few notable milestones. In New Jersey, we successfully transitioned our previous medical-only Rise Paramus dispensary to include adult use sales, a multi-year effort that's a real credit to our government affairs team. In addition, we opened Rise Hanover in Pennsylvania, adding to our retail store portfolio that exceeds 120 stores. Stepping back, the macro backdrop hasn't changed. Federal legislative uncertainty, pricing compression, and consumer discretionary pressure remain near term business headwinds. We remain confident that our team, operational discipline, brand strength, and capital position provides us with the ability to navigate these headwinds while still investing in our team and future growth opportunities. As noted in our press release, we made deliberate incremental investments in our team this quarter that pressured near-term EBITDA margins. Of all the investments we make across the business, the ones into our team have some of our highest intrinsic returns. One more thing before I hand it over to Matt. For those of you in the Philadelphia area, we'd love to see you at our Rhythm Bud Ball on August 26th. As a reminder, our Rhythm Bud Balls have become one of our favorite ways to celebrate the cannabis community through music and culture. After big nights in New York with Ferg and Chicago with Chance the Rapper, we're bringing the magic to the city of brotherly love. The acts haven't been publicly announced yet, but it's going to be a banger, and we hope to see you there. Matt, over to you.

Thanks, Anthony, and hello, everyone. From a top line perspective, revenue Driven in large part due to adult use sales launch in Minnesota along with net CPG growth and new store contributions. Pricing pressures continue to weigh on the top line even as we see solid demand. Looking forward, we expect third quarter sequential revenue to be flat due to the pricing environment. Gross profit for the second quarter was $138 million or 45% of revenue compared to $146 million or 50% of revenue year over year. The decrease in gross margin was driven by $17.5 million of brand licensing fees incurred in the current period. On a normalized basis, margins saw slight improvement over last year. Turning to OpEx, selling general administrative expenses for the second quarter were $118 million for 38% of revenue, compared to $107 million for 36% of revenue for the second quarter last year. The increase in total expenses was primarily attributable to overall compensation benefit costs along with increased costs associated with opening, acquiring, and operation of retail stores. SG&A excluded depreciation, amortization, one-time transaction costs, and stock-based comp, which we refer to as normalized operating costs, approximately $84 million compared to $74 million in the second quarter of last year. The increase year-over-year is mainly attributed to the deliberate changes to our compensation structure this quarter, as Anthony mentioned, along with other targeted investments in the business. A normalized EBITDA of $84.3 million, or 27.5%, was down slightly from last year of $28.2, due to the OPEX investments previously referenced. On the bottom line, we delivered GAAP net income of $4.9 million, or $0.02 per basic, The current year includes some benefit from 280E relief for medical cannabis, while the prior year included a loss recorded from the IP sale. We remain committed to maintaining this financial flexibility so we can invest opportunistically in growth while managing risk.

With that, I'll turn the call over to the operator for questions.

Thank you. At this time, we will conduct the question and answer session. As a reminder, to ask a question, you will need to press star 1-1 on your telephone and wait for your name to be announced. To withdraw your question, please press star 1-1 again. Please stand by while we compile the Q&A roster. Our first question comes from the line of Kenric Taihee from Canaccord Genuity. Please go ahead.

Thank you and good evening. I wonder if we could just dive into the margin profiling culture just in the context out of the flat revenue expectation in Q3. Obviously, you know, pricing pressures are still there, but you did also call out sort of in select markets, some of the moderation, promotional intensity. So when we look to that gross margin kind of actually the licensing fees, how do you see that evolving here in the second half?

Yeah, thanks for the question. This is Matt. When you look at pricing, it's a little bit of the unknown. We've seen pricing pressures continue there, and while there might be some signs of easing in a few select markets, there still is pricing pressures across that's going to weigh on the top line. As it relates to margin, the licensing fees, once that was moved to a

Thank you. If I could just pivot quickly to Virginia, obviously very topical. Given your footprint there and as strong as it's believed to be, could you speak to within the Virginia market for how long that market could be expected to be supply constrained and potential biomass availability or other constraints as we look to ramp? I think we're all just trying to handicap the second half here of 27 on a launch. without getting too far over our skis given some of your competitor commentary on those dynamics.

Yeah, Kendrick. This is Anthony here. Great question. So let's just analyze the setup here. You have some of the incumbents that have some existing capacity. We're one of the five medical operators. And then you have potentially new capacity coming on through the incremental licensing. The additional licensing step has not yet taken place. So, you know, that remains kind of a question mark. And again, this is in the backdrop of a plan July 1st, 2027 launch. So, you know, call it within 12 months at this point, just under. From the Green Thumb side, you know, we completed a capacity expansion through a second facility about 18 months ago. Candidly, we thought that adult use was going to happen sooner. And so we did the build out kind of in anticipation of that. You know, one of the things we're doing right now with the team is kind of assessing, do we have enough capacity? What are others doing? And how would that kind of translate into our ability to kind of service the market? I think one of the things that's difficult to kind of estimate is demand. You know, given Virginia's location in that kind of southeastern mid-Atlantic corridor, you know, you have a very vibrant kind of intoxicating hemp market. If the loophole does in fact close in November, we think that could kind of materially impact demand, which then would put probably incremental pressure on the supply side. So as it relates to Green Thumb, you know, we're kind of, that's the math we're kind of looking at and running in our minds in terms of how much additional capacity we'll add, you know, we'll determine that over the coming months. but we expect there to be some comply constraint within the market out of the gate but really depending on how hemp shakes out as well as how soon the state licenses other operators really kind of determine overall how long that will last.

That's some great color. Thank you, I'll get back in queue.

Great.

Thank you. Our next question comes from the line of Aaron Gray from AGP Alliance Global Partners. Please go ahead.

Hi, good evening and thank you very much for the questions. Just regarding some of the prepared remarks in terms of plans for potential up listing, just wanted to get some incremental color there. Any commentary in terms of whether or not obviously that would be post phase two rescheduling that included the whole plant? Is there any anticipation of any additional guidance from FinCEN or otherwise needed? to potentially build up list adult use as well from your conversations with either NYSE or NASDAQ. And then just talk maybe further about whether or not the plans to consolidate Rhythm were in line with that thinking of having the up listing or if that was separately involved.

Thank you. Well, second question first. I mean, separate. But I think clarity and consistent story for investors. We see this as going kind of into the new era. We're moving from Schedule 1 to federally legal DEA compliant and should open up a brand new world of investment. So we think we've got a great story. We're teeing up to get out and tell it. We think the multiple is cheap. In terms of what's required, not totally positive. So I can't give you an exact firm answer, but we know that the AOJ has to wrap up and adult use would have to be rescheduled. And then we think it's a rather fast path. But you don't know what you don't know. But we're teed up to do it and to be ready. and we think we've got a good growth story coming with a couple of things in the tank here, potentially some of the growth fueled by hemp and other things. So that's where we sit, but the next big tell is going to be the rescheduling of adult use product.

Okay, great. Thanks for that, Kovler. Second question for me, just in terms of the SG&A uptake in the quarter, just looking through the 10Q, it did seem that there was some acquisitions or some consolidation at least of some retail stores, particularly the aid stores in there. So I just wanted to ask how much of that was included within the SG&A versus just organic investments. And then bigger picture, just how you're thinking about smaller tuck-in M&A and deeper penetration within select existing states. Thank you.

Sure, I can take that. So first of all, with the SG&A, It's the combination of the incremental stores that were acquired during the quarter that have a decent SG&A profile that weighed a bit there, but it's also the compensation investments that we made that were incremental this quarter compared to last quarter that had additional weight to SG&A during the period.

and then M&A. This is Ben. I can take the M&A side, just our general appetite on M&A. I'd say it's been a very consistent approach here over the years. We look at everything. We evaluate if it makes sense or not. We're really trying to generate returns and do a positive, you know, a good return on the invested capital. We're not interested in sort of empire building or some future promise of what might happen or things like that. So it's really got to make sense to us. We've been able to find a few things. We'd rather find a great M&A deal than buy a lot of our stock. It depends how cheap the stock is, but buying and doing an M&A can get a scale, can get growth, and can be better for shareholders in the future. So we're out there looking, and it's an interesting environment given the uncertainty going with a lot of things, given the tax situation, which I can't emphasize enough how just important the tax issue is out there in terms of cash and what's going on. and how it might impact M&A. But we're out there talking and pretty active.

Okay, great. Appreciate the call. I'll jump back in the queue. Thank you.

Thank you. Our next question comes from the line of Frederico Gomez from ATB Cormac Capital Markets. Please go ahead.

Hi, good afternoon. Thanks for taking my question. When I talk about beverages, you mentioned that you're optimistic for a beverage carve-out potentially, and you mentioned that beverages may be a different consumption format from the others, and policymakers are seeing that. So I'm curious if you could elaborate on that, why beverages and not other formats like gummies, for example, and why you believe beverages could be treated differently here. Thank you.

Great. This is Ben. I can take it. My comment was less on what's going to happen from the government side and more just what's happening in the category. We're seeing beverages be sold in places, not the dispensary. So that's a big deal. You're seeing large share of liquor stores, convenience stores, out of the liquor, beer, into THC. National retailers like Target or Albertsons through Juul here in Chicago, Circle K, Total Wine, ABC, Specs. Massive THC spreads of beverages. So we see the consumers choosing this product, being happy with it, and here are the reasons. Tastes great, lower calorie, no hangover, feel great, and you don't have a problem in the morning that a lot of people feel with a lot of alcohol. So this we have a lot of confidence has a place on the shelf because consumers want it, and we don't see a lot of health and safety risk. In fact, the impairment versus alcohol and all those sorts of positive things happening there. The hemp game is an unregulated product masquerading as marijuana sold at the gas station, oftentimes imported with chemicals and untested and unknown. So what I said in the prepared remarks is we see that the distinct category from intoxicating hemp, a 5 and 10 milligram ready-to-drink beverage is different from a 1,000 milligram gummy I could buy here in Chicago a block from the office. It's just like so material to emphasize, a 1,000 milligram gummy versus a 5 or 10 milligram drink. That's what the market is today. If you go into a hemp store, 100 mg, 500 mg, huge dose, unclear what's in it, untested. That product has to go away. We are confident folks in DC will get rid of it. Over time, and I don't know if it'll be right away, it could be six months or a year later, we know this drink category is real, it will exist. It's a meaningful part of the retailer's business, it's becoming a meaningful part of the distributor's business. and pretty soon the alcohol folks are going to realize the consumer generational trends are in favor of this. And so we're going to see that. So we believe in the product. We're coming off a lot of momentum here in Chicago here this summer as consumers are really starting to become aware of this product that really didn't exist in this market as little as two years ago. So it's an exciting time, but certainly tons of uncertainty.

Thank you. Appreciate that. Second question. Just maybe going back to the comment about potential stabilization in some markets, I guess I'm curious about what do you think supports potential stabilization in the overall market on a go-forward basis? What do we need to see for that to happen and in which part of the cycle are we? Is the market consolidating? Maybe unprofitable players leaving those markets? Could it be related to the upcoming intoxicating handpan? What are you expecting to see and which part of the cycle are we? Thank you.

Yeah, that's a great question. I wish the crystal ball had a clear answer for us there. Very, very murky. I mean, you said it, you called it out kind of all the confluence of factors right now that's impacting kind of the supply demand within the state markets and then nationally. What it's resulted in is just really kind of price erosion that we've seen over the last several years. So, you know, we've got pockets of stabilization that kind of Matt alluded to, you know, and I think, you know, Ohio is kind of no secret. You know, the hemp ban there seems to have really been a positive thing for the market. And I'll tell you kind of, you know, in speaking with our Ohio teams, yes, we're seeing price stabilize and we're seeing kind of, you know, as a result, revenue go up as fast as units continue to kind of increase due to consumer demand. So where we are in the cycle, it's still very murky in anyone's guess. We do think that a closure of the hemp loophole would provide kind of greater price level stabilization. But the reality is that there continues to be kind of supply demand imbalances within a number of the existing states and still need time to kind of clear out. You know, we use the term kind of water finds its lowest point in capitalism. There's no kind of difference here. And we think it'll just take time for all this to kind of become more apparent to us. And so we're watching kind of the factors that impact that supply demand and balance. Hemp is a big one. What happens at the federal level? You know, it could go either way. If you see rescheduling, you know, could result in an influx of capital and then we could be in the same situation over time where, you know, there could be imbalances created from that supply demand. So we're watching it closely. But we think, you know, just like everyone, we're anxious to kind of see some level of stabilization happen because it's been a very challenging operating environment for the team and the rest of the industry.

Thank you very much.

Thank you. Our next question comes from Pablo Zujanic from Zujanic and Associates. Please go ahead.

Thank you and good afternoon everyone. Just going back to green thumb consolidating rhythm, why not the other way around, right? If you get re-scheduled, and then Rhythm Consolidates Green Thumb. That would be a much, much faster path. Rhythm is already NASDAQ listed. Can you explain why do you want to do it the other way around? Thank you.

Pablo, this is Matt. So it's not really an option at this point for Rhythm to consolidate Green Thumb because Green Thumb once, you know, assuming the vote goes as anticipated, Green Thumb will then control Rhythm Forcing consolidation of rhythm into GTI's financials. So the opposite way of consolidating is just not possible from a GAAP accounting perspective.

No, I know, but is this just an accounting issue or is it a transaction in terms of GTI buying rhythm?

There's not any buying happening. The shareholders are approving the ability for an owner to go over the 49.9% that is currently in there. Once that's removed... because then the ability of Green Thumb to do it, though Green Thumb doesn't have to do anything, no economic transaction, nothing changes, but because that's open according to GAAP accounting, we will then consolidate Rhythm's results into Green Thumb.

Right. But sorry to harp on the point, right, but I always thought, and I'm sure I'm wrong, I guess, that having Rhythm being NASDAQ listed Once you've got a regular schedule, that would give you a very, very fast path to be uplisted because then rhythm, NASA listed, could acquire all of GTI. What's wrong with my thinking there?

That's not a very fast path. There's complicated tax ramifications of all those transactions versus list green thumb on the NASDAQ or New York Stock Exchange. That's a fast path. You've seen others do it. There's really not a big delay there. The transaction you outlined has a lot of complicating factors that would create more friction that we don't... We're evaluating it all, but it's a harder transaction to effectuate versus the former.

Thank you. That's a very good call. I want to ask a two-part question regarding the states. In the case of Georgia, again, maybe I'm wrong, but I thought you owned 10% of Theta 2 there. I want to understand whether that gives you a path to control and ownership. of that license operator in Georgia, which is only one of six. And also related to states, you know, you're seeing Virio Growth make three acquisitions in Florida. Are we going to see them some get more active on the M&A front in Florida at some point? Thank you.

Hey, Pablo. Anthony here. I'll take both of those. Georgia, you are correct that we do have an investment in a Georgia operator, Theratru. We are watching that market very closely in terms of kind of next steps there. I'd say it's just preliminary to kind of to make a call on that front, but yeah. We are certainly watching what's happening in Georgia. We're very excited about it, and we're excited to see what that market can become. I'll tell you, we've got a full plate right now with Virginia and Texas. We're not ignoring Georgia, but right now we're spending a lot of time and effort on those two specific markets. Your second question about Florida. Look, I think what you're going to see in Florida from us is new store openings. You know, we've got anywhere from five to seven incremental stores opening between now and the end of the year. And we have a path for additional stores in 2027. So that's one of the states where we're seeing nice same store sales growth. We're not going to break that out, but we're seeing nice progress within that market. And that's another market that we feel if there is kind of a hemp band that goes into place, that's a market right now that's got a lot of hemp being sold. and so that should that should only kind of provide additional kind of growth support for that market but for us right now it's head down open up the stores and continue to kind of lean into the playbook that's worked for us we've seen some of the assets that have come to market there's been a lot of hair on them and it just hasn't made sense for us but you know as Ben kind of mentioned we'll look at everything and eyes wide open but right now head down and our plan in forward is to continue to kind of open stores via the old-fashioned way.

Thanks, Anthony. And Ben, if I can add, just one more, if I may. Do you want to make any comments in this public forum about your relationship with the folks at the MSOS ETF? Their latest disclosure, as of yesterday, they own about 24 million shares of Green Sound, you know, through derivative swaps. Any comments on that? Thank you.

Sure. Thanks, Pablo.

Yeah, they're a significant shareholder. We'd love to be in more contact with them. We've reached out. Maybe if anybody on the call has good communications with them, they're certainly a participant in the multi-state operator market. And the multiples among the operators have changed as a result of really they're the only institutional buyer in the space of size. And so there's a big disparity in the multiples. If there's any fundamental or actual institutional investors out there that are interested in investing either in the Canadian or on the way to the U.S. exchange, We think it creates an amazing opportunity for shareholders. We want to have a good relationship. We've reached out several times. We'd love to speak to them. And we're excited about the potential uplistings and the potential rescheduling.

Thank you. That's all for me.

This concludes the question and answer session. I would now like to turn it back to Ben Kovler for closing remarks.

Thanks, everybody, for joining. Buckle up. We think the next six months could potentially be the most significant in the cannabis landscape in the last 12 years we've been running the business. We're tuned in. We're excited. The team is ready. And we'll talk to you in 90 days. Thank you.

Thank you for your participation in today's conference. This does conclude the program. You may now disconnect.